We want every man with prostate cancer – or at risk of it - to have access to the same high-quality diagnosis, treatment and care, no matter where in the UK he lives.

The Prostate Cancer UK Best Practice Pathway makes this possible.

BPP example

Extract from Best Practice Pathway: Treatment, Active Surveillance

The big idea

Developed to support healthcare professionals at the front line of prostate cancer diagnosis and care, our Best Practice Pathway starts before referral, guiding healthcare professionals on the ways to achieve early diagnosis in those men at higher than average risk of the disease.

The diagnostic, treatment and support pathways set out the most up-to-date, cutting-edge research-led innovations - so that healthcare professionals are equipped and supported to provide the very latest evidence-based best practice to their patients.

Available in easy to use flowcharts and regularly updated to keep up with the fast-moving pace of change in prostate cancer research and practice, the Prostate Cancer UK Best Practice Pathway offers healthcare professionals across the UK the route to achieve pathway transformation and deliver the highest quality prostate cancer diagnosis, treatment and care.

  • Diagnostic pathway



    The aim of this pathway is to transform men’s experiences from the pre-diagnostic phase and beyond, using clinical consensus on ways to improve the use of the PSA test for men without symptoms and newly published clinical research that offers the potential to reduce unnecessary biopsies.

    Diagnostic pathway (PDF)
    Diagnostic pathway commentary (PDF)

  • Treatment pathway



    Just as every man is an individual, every treatment pathway is individual and needs to be tailored to the needs of the man. Each man must have the opportunity to make an informed choice about their treatment pathway, having been given detailed information about the treatments available for the stage of their disease, the side effects associated with each of these treatments and the outcomes the treatments will provide. For men with low risk cancer, active surveillance must be presented as a treatment option alongside surgery and radiotherapy.

    Treatment pathway (PDF)
    Treatment pathway - treatment by risk stratification (PDF)
    Treatment pathway - commentary (PDF)

  • Support pathway



    Prostate cancer survival is improving and has tripled in the last 40 years in the UK. In the 1970s, a quarter of men diagnosed with prostate cancer survived their disease beyond ten years, now it's more than 8 in 10.

    More men are living with and after prostate cancer, which means that more men are living with a variety of supportive care needs. These needs may be caused by the physical and psychological side effects of their treatment, as well as the broader impact of the diagnosis on the emotional, practical and social aspects of their lives. Additionally, 60% of men with prostate cancer are living with other health conditions. As well as assessing health status prior to starting treatment, using approaches to care planning that focus on the entire well-being of a man with prostate cancer should help address these multi-factorial needs. 

    Better support for people after cancer treatment can improve quality of life, and promotes behaviours that may prevent recurrence or complications resulting from the unmanaged consequences of treatments.
    Good support can also equip people and their families with self-management skills. For example self-management interventions have been assessed in survivors and found to improve urinary symptoms with positive results. Interventions focused on coping skills, diet and exercise can improve quality of life for men with prostate cancer.

    Full support pathway with commentary (PDF)

How have we developed it?

Prostate Cancer UK worked with clinical experts from urology, medical and clinical oncology, and radiology. We also secured expert input from clinical nurse specialists, general practitioners and the National Institute for Clinical Excellence to develop the Best Practice Pathway.

In addition, the Best Practice Pathway has been peer reviewed by a Clinical Reference Group (CRG) that has included representatives from all the relevant professional bodies and leading prostate cancer clinical researchers.

The CRG will continue to work with us to make sure that the best practice pathway remains up-to-date and robust.


  • How have we decided what to recommend as best practice?  

    • We have included new, recently published research that is delivering breakthrough changes in prostate cancer diagnosis and treatment, for example the latest results of the STAMPEDE trial.
    • We have aligned with NICE Prostate Cancer Guidelines CG175 recommendations, where they are not superseded by recently published research them.
    • We have drawn from our comprehensive Prostate Cancer UK health information resources, which are regularly peer reviewed and certified by the Information Standard, which is a quality mark for reliable health and social care information. This means that we follow best practice when producing health information to make sure that it is up-to-date, evidence-based, clinically accurate, reviewed by people affected by prostate cancer, accessible and easy to read.
  • How is the Best Practice Pathway different to the NICE Prostate Cancer Guidelines?  

    • Our medical research programme and the connections we have with the prostate cancer medical research world means our Best Practice Pathway can keep pace with new developments in prostate cancer diagnosis and treatment
    • We have first-hand insight into patient experience provided by the thousands of men (and their families) who regularly engage with us and can use this to shape the Best Practice Pathway.
  • When will the Best Practice Pathway be updated and why?  

    • We want to make sure that the Best Practice Pathway includes new practice changing medical research and other new evidence. That’s why we will aim to update the Best Practice Pathway every 6 months